Gleevec® or Glivec® - Imatinib
Chronic Myeloid Leukemia
''Imatinib was developed in the late 1990s by biochemist Nicholas Lydon, a former researcher for Novartis, and oncologist Brian Druker of Oregon Health and Science University (OHSU). Other major contributions to imatinib development were made by Carlo Gambacorti-Passerini, a physician scientist at University of Milano Bicocca, Italy, John Goldman at Royal Hammersmith Hospital in London, UK, and later on by Charles Sawyers of Memorial Sloan-Kettering Cancer Center who led the clinical trials confirming its efficacy in CML''
Extract from Wikipedia
"Jürg Zimmermann, a medicinal chemist, is the chemical inventor of the compound STI571 also called Gleevec® or Glivec®
''
Extract from Novartis
VIDEOS
Glivec (imatinib mesilate) Mechanism of Action -- from xvivo
July 7, 2018, xvivo
Spotlight on Testing: Imatinib Mesylate
May 23, 2018, ARUP Laboratories
400mg imatinib as good as 800mg for 10 year CML survival
July 6, 2017, ecancer
What are the efficacy and safety considerations of imatinib therapy?
April 29, 2016, MediCom Oncology
Side Effects Associated With Gleevec for GIST
October 26, 2015, curetoday
Brian Druker (OHSU) Part 1: Imatinib (Gleevec): A Targeted Cancer Therapy
March 29, 2010, iBiology
Gleevec®’s effects on Tyrosine Kinase
June 20, 2007, URIanimation
Glivec (imatinib mesilate) Mechanism of Action -- from xvivo
July 7, 2018, xvivo
Spotlight on Testing: Imatinib Mesylate
May 23, 2018, ARUP Laboratories
400mg imatinib as good as 800mg for 10 year CML survival
July 6, 2017, ecancer
What are the efficacy and safety considerations of imatinib therapy?
April 29, 2016, MediCom Oncology
Side Effects Associated With Gleevec for GIST
October 26, 2015, curetoday
Brian Druker (OHSU) Part 1: Imatinib (Gleevec): A Targeted Cancer Therapy
March 29, 2010, iBiology
Gleevec®’s effects on Tyrosine Kinase
June 20, 2007, URIanimation
CLINICAL TRIALS
The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia (2017-2018)
The purpose of this pilot study is to investigate whether some patients who were started on a 2G-TKI as first-line treatment can be safely switched to imatinib, a first-generation TKI, while maintaining or even deepening the molecular response as a cost-effective treatment.
The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia (2017-2018)
The purpose of this pilot study is to investigate whether some patients who were started on a 2G-TKI as first-line treatment can be safely switched to imatinib, a first-generation TKI, while maintaining or even deepening the molecular response as a cost-effective treatment.
ARTICLES
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib
September 11, 2023, Blood Cancer Journal
Switch From Imatinib to Dasatinib May Benefit Certain Patients With CML-CP
May 7, 2020, Oncology Learning Network
Early Switch to Dasatinib From First-Line Imatinib May Benefit Patients With Ph+ CML
April 21, 2020, Oncology Learning Network
Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study
April 7, 2020, PubMed
A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy
November 13, 2019, ASH 2019
Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?
November 13, 2019, ASH 2019
Comparable Efficacy and Safety of Chinese Generic Imatinib and Branded Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Study
November 13, 2019, ASH2019
Evaluation of anemia after long-term treatment with imatinib in chronic myeloid leukemia patients in chronic phase
June 14,2019, PubMed
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
December 4, 2018, NCBI
Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study
August 2018, Springer Link
Pediatric CML: Imatinib Effective in the Front Line
February 22, 2018, Cancer Therapy Advisor
10-Year Outcome of Chronic Myeloid Leukemia Patients Resistant to Frontline Imatinib
December 2017, ASH2017
Persistence with Generic Imatinib for Chronic Myeloid Leukemia: A Matched Cohort Study
December 2017, ASH2017
Preliminary Experience of Imatinib after Nilotinib in the First Line Treatment of Chronic Myeloid Leukemia
December 2017, ASH2017
CML Patients Approach Normal Life Expectancy With Imatinib Treatment
July 21, 2017, Cancer Network Hematology
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
March 9, 2017, NEJM
Cancer Pill Gleevec Keeps Patients Alive and Well for a Decade
March 9, 2017, NBCNews
Long-Term Treatment with Imatinib Is Associated with Decreased Estimated Glomerular Filtration Rate and Hemoglobin Level in Patients with Chronic Myelogenous Leukemia
December 2016, ASH2016
A Lower dosage of imatinib is sufficient to maintain undetectable disease in patients with chronic myeloid leukemia with long-term LOW-grade toxicity of the treatment.
May 18, 2015, PublMed
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV
February 13, 2015, Leukemia
Prospective Histomorphometric and DXA Evaluation of Bone Remodeling in Imatinib-Treated CML Patients: Evidence for Site-Specific Skeletal Effects.
November 8, 2012, PublMed
Is Imatinib Still an Acceptable First-Line Treatment for CML in Chronic Phase?
October 12, 2012, Cancer Network
Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib
June 1, 2012, Haematalogica
Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial
February 7, 2012, Haematologica
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib
September 11, 2023, Blood Cancer Journal
Switch From Imatinib to Dasatinib May Benefit Certain Patients With CML-CP
May 7, 2020, Oncology Learning Network
Early Switch to Dasatinib From First-Line Imatinib May Benefit Patients With Ph+ CML
April 21, 2020, Oncology Learning Network
Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study
April 7, 2020, PubMed
A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy
November 13, 2019, ASH 2019
Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?
November 13, 2019, ASH 2019
Comparable Efficacy and Safety of Chinese Generic Imatinib and Branded Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Study
November 13, 2019, ASH2019
Evaluation of anemia after long-term treatment with imatinib in chronic myeloid leukemia patients in chronic phase
June 14,2019, PubMed
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
December 4, 2018, NCBI
Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study
August 2018, Springer Link
Pediatric CML: Imatinib Effective in the Front Line
February 22, 2018, Cancer Therapy Advisor
10-Year Outcome of Chronic Myeloid Leukemia Patients Resistant to Frontline Imatinib
December 2017, ASH2017
Persistence with Generic Imatinib for Chronic Myeloid Leukemia: A Matched Cohort Study
December 2017, ASH2017
Preliminary Experience of Imatinib after Nilotinib in the First Line Treatment of Chronic Myeloid Leukemia
December 2017, ASH2017
CML Patients Approach Normal Life Expectancy With Imatinib Treatment
July 21, 2017, Cancer Network Hematology
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
March 9, 2017, NEJM
Cancer Pill Gleevec Keeps Patients Alive and Well for a Decade
March 9, 2017, NBCNews
Long-Term Treatment with Imatinib Is Associated with Decreased Estimated Glomerular Filtration Rate and Hemoglobin Level in Patients with Chronic Myelogenous Leukemia
December 2016, ASH2016
A Lower dosage of imatinib is sufficient to maintain undetectable disease in patients with chronic myeloid leukemia with long-term LOW-grade toxicity of the treatment.
May 18, 2015, PublMed
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV
February 13, 2015, Leukemia
Prospective Histomorphometric and DXA Evaluation of Bone Remodeling in Imatinib-Treated CML Patients: Evidence for Site-Specific Skeletal Effects.
November 8, 2012, PublMed
Is Imatinib Still an Acceptable First-Line Treatment for CML in Chronic Phase?
October 12, 2012, Cancer Network
Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib
June 1, 2012, Haematalogica
Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial
February 7, 2012, Haematologica
